Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
|Videos|May 18, 2020
Supplements and Featured Publications
- Therapeutic Changes in HER2+ Breast Cancer
- Volume 1
- Issue 1
Novel Treatments in HER2-Positive Breast Cancer
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Advertisement
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Supported by an unrestricted educational grant by Daiichi Sankyo
Articles in this issue
Advertisement
Related to this article
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Paolo Tarantino, MD, PhD, discusses key data with ADCs in breast cancer that were presented at ASCO 2026.
Andrew H. Ko, MD, discusses how TTFields works and data that supported the FDA approval of Optune Pax for patients with pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Docirbrutinib Yields High Response Rates in MCL and CLL
4
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
5